Although several studies suggest that presence of these fusion genes in prostate cancer, TMPRSS2-ERG in particular, is associated with more aggressive malignancy and worse clinical prognoses, not all studies agree [15,152,156,157,158,159,160,161]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.